Cargando…
Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study
Bisphosphonates are used as first-line treatment for the prevention of fragility fracture (FF); they act by inhibiting osteoclast-mediated bone resorption. The timing of their administration after FF surgery is controversial; thus, we compared the incidence of second FF, surgery for second FF, and a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229144/ https://www.ncbi.nlm.nih.gov/pubmed/34201202 http://dx.doi.org/10.3390/jcm10122541 |
_version_ | 1783712908273778688 |
---|---|
author | Wu, Meng-Huang Lin, Yu-Sheng Wu, Christopher Lee, Ching-Yu Chen, Yi-Chia Huang, Tsung-Jen Cheng, Jur-Shan |
author_facet | Wu, Meng-Huang Lin, Yu-Sheng Wu, Christopher Lee, Ching-Yu Chen, Yi-Chia Huang, Tsung-Jen Cheng, Jur-Shan |
author_sort | Wu, Meng-Huang |
collection | PubMed |
description | Bisphosphonates are used as first-line treatment for the prevention of fragility fracture (FF); they act by inhibiting osteoclast-mediated bone resorption. The timing of their administration after FF surgery is controversial; thus, we compared the incidence of second FF, surgery for second FF, and adverse events associated with early initiation of bisphosphonates (EIBP, within 3 months of FF surgery) and late initiation of bisphosphonates (LIBP, 3 months after FF surgery) in bisphosphonate-naïve patients. This retrospective population-based cohort study used data from Taiwan’s Health and Welfare Data Science Center (2004–2012). A total of 298,377 patients received surgeries for FF between 2006 and 2010; of them, 1209 (937 EIBP and 272 LIBP) received first-time bisphosphonates (oral alendronate, 70 mg, once a week). The incidence of second FF (subdistribution hazard ratio (SHR) = 0.509; 95% confidence interval (CI): 0.352–0.735), second FF surgery (SHR = 0.452; 95% CI: 0.268–0.763), and adverse events (SHR = 0.728; 95% CI: 0.594–0.893) was significantly lower in the EIBP group than in the LIBP group. Our findings indicate that bisphosphonates should be initiated within 3 months after surgery for FF. |
format | Online Article Text |
id | pubmed-8229144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82291442021-06-26 Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study Wu, Meng-Huang Lin, Yu-Sheng Wu, Christopher Lee, Ching-Yu Chen, Yi-Chia Huang, Tsung-Jen Cheng, Jur-Shan J Clin Med Article Bisphosphonates are used as first-line treatment for the prevention of fragility fracture (FF); they act by inhibiting osteoclast-mediated bone resorption. The timing of their administration after FF surgery is controversial; thus, we compared the incidence of second FF, surgery for second FF, and adverse events associated with early initiation of bisphosphonates (EIBP, within 3 months of FF surgery) and late initiation of bisphosphonates (LIBP, 3 months after FF surgery) in bisphosphonate-naïve patients. This retrospective population-based cohort study used data from Taiwan’s Health and Welfare Data Science Center (2004–2012). A total of 298,377 patients received surgeries for FF between 2006 and 2010; of them, 1209 (937 EIBP and 272 LIBP) received first-time bisphosphonates (oral alendronate, 70 mg, once a week). The incidence of second FF (subdistribution hazard ratio (SHR) = 0.509; 95% confidence interval (CI): 0.352–0.735), second FF surgery (SHR = 0.452; 95% CI: 0.268–0.763), and adverse events (SHR = 0.728; 95% CI: 0.594–0.893) was significantly lower in the EIBP group than in the LIBP group. Our findings indicate that bisphosphonates should be initiated within 3 months after surgery for FF. MDPI 2021-06-08 /pmc/articles/PMC8229144/ /pubmed/34201202 http://dx.doi.org/10.3390/jcm10122541 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wu, Meng-Huang Lin, Yu-Sheng Wu, Christopher Lee, Ching-Yu Chen, Yi-Chia Huang, Tsung-Jen Cheng, Jur-Shan Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study |
title | Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study |
title_full | Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study |
title_fullStr | Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study |
title_full_unstemmed | Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study |
title_short | Timing of Bisphosphonate (Alendronate) Initiation after Surgery for Fragility Fracture: A Population-Based Cohort Study |
title_sort | timing of bisphosphonate (alendronate) initiation after surgery for fragility fracture: a population-based cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229144/ https://www.ncbi.nlm.nih.gov/pubmed/34201202 http://dx.doi.org/10.3390/jcm10122541 |
work_keys_str_mv | AT wumenghuang timingofbisphosphonatealendronateinitiationaftersurgeryforfragilityfractureapopulationbasedcohortstudy AT linyusheng timingofbisphosphonatealendronateinitiationaftersurgeryforfragilityfractureapopulationbasedcohortstudy AT wuchristopher timingofbisphosphonatealendronateinitiationaftersurgeryforfragilityfractureapopulationbasedcohortstudy AT leechingyu timingofbisphosphonatealendronateinitiationaftersurgeryforfragilityfractureapopulationbasedcohortstudy AT chenyichia timingofbisphosphonatealendronateinitiationaftersurgeryforfragilityfractureapopulationbasedcohortstudy AT huangtsungjen timingofbisphosphonatealendronateinitiationaftersurgeryforfragilityfractureapopulationbasedcohortstudy AT chengjurshan timingofbisphosphonatealendronateinitiationaftersurgeryforfragilityfractureapopulationbasedcohortstudy |